Bill and Melinda Gates Foundation donations made to Global Alliance for TB Drug Development

This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of July 2024. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.

Table of contents

Basic donor information

ItemValue
Country United States
Wikipedia pagehttps://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation
Best overview URLhttps://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation
Facebook username gatesfoundation
LinkedIn username bill-&-melinda-gates-foundation
Websitehttps://www.gatesfoundation.org/
Donations URLhttps://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database
Twitter usernamegatesfoundation
Page on philosophy informing donationshttps://www.gatesfoundation.org/What-We-Do
Grant application process pagehttps://www.gatesfoundation.org/How-We-Work/General-Information/Grantseeker-FAQ
Regularity with which donor updates donations datacontinuous updates
Regularity with which Donations List Website updates donations data (after donor update)irregular
Lag with which donor updates donations datamonths
Lag with which Donations List Website updates donations data (after donor update)years
Data entry method on Donations List WebsiteSQL insertion commands generated by script https://github.com/riceissa/gates-foundation-iati-processing

Brief history: The Gates Foundation launched in 2000, with precursors starting in the 1990s, financed by the personal wealth of co-founder Bill Gates from Microsoft. Starting 2005, it scaled up its giving significantly after a large funding commitment from Warren Buffett

Brief notes on broad donor philosophy and major focus areas: See https://www.gatesfoundation.org/Who-We-Are/General-Information/Foundation-Factsheet for the grantmaking areas. The four grantmaking areas are the Global Development Program, Global Health Program, Global Policy and Advocacy, and United States Program. Within the United States Program the focus is on K-12 education, the Internet, and emergency relief

Notes on grant publication logistics: Although the Gates Foundation has a grants database on its website, as well as individual grant pages for every grant, we use the IATI data instead, because it can be processed programmatically (the data on the site does not allow for full data download or easy programmatic processing). This leads to a few problems: first, IATI data does not include grants made in the United States, since it focuses on development assistance (DA) spending. Second, IATI data is updated more infrequently. Third, it may sometimes omit some information that is present in the grants database

Full donor page for donor Bill and Melinda Gates Foundation

Basic donee information

ItemValue
Country South Africa
Facebook page TBAllianceCE
Websitehttps://www.tballiance.org/
Donate pagehttps://www.tballiance.org/donate
Twitter usernametballiance
Wikipedia pagehttps://en.wikipedia.org/wiki/TB_Alliance

Full donee page for donee Global Alliance for TB Drug Development

Donor–donee relationship

Item Value

Donor–donee donation statistics

Cause areaCountMedianMeanMinimum10th percentile 20th percentile 30th percentile 40th percentile 50th percentile 60th percentile 70th percentile 80th percentile 90th percentile Maximum
Overall 13 1,640,000 31,644,373 -14,310,323 0 0 0 393,508 1,640,000 1,885,605 25,000,000 104,403,823 145,000,000 164,910,038
Global health 13 1,640,000 31,644,373 -14,310,323 0 0 0 393,508 1,640,000 1,885,605 25,000,000 104,403,823 145,000,000 164,910,038

Donation amounts by cause area and year

If you hover over a cell for a given cause area and year, you will get a tooltip with the number of donees and the number of donations.

Note: Cause area classification used here may not match that used by donor for all cases.

Cause area Number of donations Total 2018 2017 2016 2015 2014 2010 2006
Global health (filter this donor) 13 411,376,851.67 -16,422,381.33 -15,433,741.00 393,508.00 146,885,605.00 26,640,000.00 164,910,038.00 104,403,823.00
Total 13 411,376,851.67 -16,422,381.33 -15,433,741.00 393,508.00 146,885,605.00 26,640,000.00 164,910,038.00 104,403,823.00

Graph of spending by cause area and year (incremental, not cumulative)

Graph of spending should have loaded here

Graph of spending by cause area and year (cumulative)

Graph of spending should have loaded here

Full list of documents in reverse chronological order (0 documents)

There are no documents associated with this combination of donor and donee.

Full list of donations in reverse chronological order (13 donations)

Graph of all donations (with known year of donation), showing the timeframe of donations

Graph of donations and their timeframes
Amount (current USD)Amount rank (out of 13)Donation dateCause areaURLInfluencerNotes
-259,272.3392018-03-30Global health/basic health carehttps://iatiregistry.org/publisher/bmgf-- to accelerate global health drug development and registration by creating a public database of chemistry, manufacturing, and controls (CMC) regulatory requirements for target global health countries; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
-14,310,323.00132018-02-22Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to accelerate development of anti-tuberculosis treatments by filling the drug development pipeline with novel candidates, developing single drug candidates, and working as a part of the Critical Path to TB drug Regimens; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
-1,852,786.00102018-02-22Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to develop and introduce novel drugs and drug regimens to make treatment of all forms of TB more effective, safe and affordable; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
-12,102,089.00122017-04-18Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to support the Shortening Treatments by Advancing Novel Drugs (STAND) trial, which is the first Phase III registration trial testing a drug regimen for use against both Tuberculosis and multidrug-resistant Tuberculosis (MDR-TB); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
-5,428,000.00112017-04-06Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to support the Shortening Treatments by Advancing Novel Drugs (STAND) trial, which is the first Phase III registration trial testing a drug regimen for use against both Tuberculosis and multidrug-resistant Tuberculosis (MDR-TB); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
2,096,348.0052017-02-02Global health/basic health carehttps://iatiregistry.org/publisher/bmgf-- to accelerate global health drug development and registration by creating a public database of chemistry, manufacturing, and controls (CMC) regulatory requirements for target global health countries; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
393,508.0082016-07-17Global health/basic health carehttps://iatiregistry.org/publisher/bmgf-- to accelerate global health drug development and registration by creating a public database of chemistry, manufacturing, and controls (CMC) regulatory requirements for target global health countries; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
145,000,000.0022015-11-10Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to develop and introduce novel drugs and drug regimens to make treatment of all forms of TB more effective, safe and affordable; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
1,885,605.0062015-10-23Global health/basic health carehttps://iatiregistry.org/publisher/bmgf-- to accelerate global health drug development and registration by creating a public database of chemistry, manufacturing, and controls (CMC) regulatory requirements for target global health countries; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
25,000,000.0042014-11-03Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to support the Shortening Treatments by Advancing Novel Drugs (STAND) trial, which is the first Phase III registration trial testing a drug regimen for use against both Tuberculosis and multidrug-resistant Tuberculosis (MDR-TB); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
1,640,000.0072014-05-06Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to foster exploration and innovation needed to identify, develop and deliver the right global health products to those most in need; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
164,910,038.0012010-11-19Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to accelerate development of anti-tuberculosis treatments by filling the drug development pipeline with novel candidates, developing single drug candidates, and working as a part of the Critical Path to TB drug Regimens; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
104,403,823.0032006-05-09Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to decrease tuberculosis mortality by developing new anti-TB treatments. to decrease tuberculosis mortality by developing new anti-TB treatments. Investment start date: 5/1/2006 to end date: 5/1/2011. Grantee name: Global Alliance for TB Drug Development; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.